Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.54)
# 901
Out of 5,015 analysts
208
Total ratings
53.23%
Success rate
4.13%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $215 → $245 | $230.50 | +6.29% | 16 | Sep 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $975 → $825 | $833.49 | -1.02% | 13 | Aug 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $407.79 | +18.93% | 4 | Aug 5, 2025 | |
| AMGN Amgen | Reiterates: Neutral | $305 | $290.13 | +5.13% | 17 | Jun 24, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $43.96 | +25.11% | 16 | Apr 23, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $564.63 | +23.09% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $24.78 | -3.15% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $43.70 | - | 1 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $85.99 | -1.15% | 11 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $117.18 | +6.67% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $136.63 | +20.76% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $25.16 | -20.51% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $146.57 | +22.81% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $88.10 | +13.51% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $31.23 | +92.12% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.36 | +120.59% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.31 | +587.02% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $60.04 | +58.23% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $14.00 | +42.86% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $86.80 | -15.90% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $3.02 | +297.35% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $2.28 | -34.21% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.94 | +139.29% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $199.82 | +90.17% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $83.80 | -2.15% | 5 | Jan 16, 2019 |
AbbVie
Sep 15, 2025
Maintains: Overweight
Price Target: $215 → $245
Current: $230.50
Upside: +6.29%
Eli Lilly and Company
Aug 13, 2025
Maintains: Overweight
Price Target: $975 → $825
Current: $833.49
Upside: -1.02%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $407.79
Upside: +18.93%
Amgen
Jun 24, 2025
Reiterates: Neutral
Price Target: $305
Current: $290.13
Upside: +5.13%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $43.96
Upside: +25.11%
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $564.63
Upside: +23.09%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $24.78
Upside: -3.15%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $43.70
Upside: -
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $85.99
Upside: -1.15%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $117.18
Upside: +6.67%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $136.63
Upside: +20.76%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $25.16
Upside: -20.51%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $146.57
Upside: +22.81%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $88.10
Upside: +13.51%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $31.23
Upside: +92.12%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.36
Upside: +120.59%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.31
Upside: +587.02%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $60.04
Upside: +58.23%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $14.00
Upside: +42.86%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $86.80
Upside: -15.90%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $3.02
Upside: +297.35%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $2.28
Upside: -34.21%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.94
Upside: +139.29%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $199.82
Upside: +90.17%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $83.80
Upside: -2.15%